Literature DB >> 32105810

A Primer on Interstitial Lung Disease and Thoracic Radiation.

Christopher D Goodman1, Suzan F M Nijman2, Suresh Senan2, Esther J Nossent2, Christopher J Ryerson3, Inderdeep Dhaliwal1, X Melody Qu1, Joanna Laba1, George B Rodrigues1, David A Palma4.   

Abstract

Interstitial lung disease (ILD) is a term used to describe a heterogeneous group of lung disorders with characteristic clinical and imaging features. Patients with ILD are at an increased risk of developing NSCLC, which is frequently medically comorbid, often precluding operative management. In this scenario, radiotherapy (RT) is generally recommended; however, ILD is known to increase the risk of RT-related toxicity. Recommendations for treatment with appropriately individualized risks and benefits are thus dependent on integration of patient-, ILD-, and cancer-specific factors. We aim to provide an overview of ILD for the thoracic oncologist, an assessment of risk of thoracic RT in patients with ILD, and evidence-based recommendations for treatment in a variety of clinical scenarios.
Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical decision making; Interstitial lung disease; Thoracic radiation; Toxicity

Mesh:

Year:  2020        PMID: 32105810     DOI: 10.1016/j.jtho.2020.02.005

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  10 in total

Review 1.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 4: systematic review of evidence involving SBRT and ablation.

Authors:  Henry S Park; Frank C Detterbeck; David C Madoff; Brett C Bade; Ulas Kumbasar; Vincent J Mase; Andrew X Li; Justin D Blasberg; Gavitt A Woodard; Whitney S Brandt; Roy H Decker
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

2.  Treatment outcomes of patients with stage III non-small cell lung cancer and interstitial lung diseases receiving intensity-modulated radiation therapy: A single-center experience of 85 cases.

Authors:  Linfang Wu; Shijun Zhao; Hui Huang; Wenqing Wang; Tao Zhang; Zongmei Zhou; Qinfu Feng; Jun Liang; Zefen Xiao; Zhouguang Hui; Jima Lv; Nan Bi; Luhua Wang
Journal:  Thorac Cancer       Date:  2022-04-22       Impact factor: 3.223

3.  Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease.

Authors:  Yuanjun Liu; Yaoyao Zhu; Ran Wu; Min Hu; Lingnan Zhang; Qingren Lin; Denghu Weng; Xiaojiang Sun; Yu Liu; Yaping Xu
Journal:  Transl Lung Cancer Res       Date:  2020-12

4.  Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer.

Authors:  Nan Bi; Luhua Wang; Kunpeng Xu; Jun Liang; Tao Zhang; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Zefen Xiao; Zhouguang Hui; Jima Lu; Xin Wang; Lei Deng; Wenyang Liu; Jianyang Wang; Yirui Zhai; Jie Wang
Journal:  Thorac Cancer       Date:  2021-01-27       Impact factor: 3.500

5.  Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy.

Authors:  Fangjuan Li; Hui Liu; Hongyu Wu; Shixiong Liang; Yaping Xu
Journal:  Radiat Oncol       Date:  2021-04-13       Impact factor: 3.481

6.  A comparative study of the sarcopenia screening in older patients with interstitial lung disease.

Authors:  Masatoshi Hanada; Noriho Sakamoto; Hiroshi Ishimoto; Takashi Kido; Takuto Miyamura; Masato Oikawa; Hiroki Nagura; Rina Takeuchi; Yurika Kawazoe; Shuntaro Sato; S Ahmed Hassan; Yuji Ishimatsu; Hideaki Takahata; Hiroshi Mukae; Ryo Kozu
Journal:  BMC Pulm Med       Date:  2022-01-25       Impact factor: 3.317

Review 7.  Radiation-induced lung injury - what do we know in the era of modern radiotherapy?

Authors:  Marek Konkol; Paweł Śniatała; Piotr Milecki
Journal:  Rep Pract Oncol Radiother       Date:  2022-07-29

8.  Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic.

Authors:  Lukas Käsmann; Julian Taugner; Alexander Nieto; Claus Belka; Chukwuka Eze; Farkhad Manapov
Journal:  J Clin Med       Date:  2022-09-27       Impact factor: 4.964

Review 9.  Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee.

Authors:  Robert W Mutter; J Isabelle Choi; Rachel B Jimenez; Youlia M Kirova; Marcio Fagundes; Bruce G Haffty; Richard A Amos; Julie A Bradley; Peter Y Chen; Xuanfeng Ding; Antoinette M Carr; Leslie M Taylor; Mark Pankuch; Raymond B Mailhot Vega; Alice Y Ho; Petra Witt Nyström; Lisa A McGee; James J Urbanic; Oren Cahlon; John H Maduro; Shannon M MacDonald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-05-25       Impact factor: 8.013

Review 10.  Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review.

Authors:  Lukas Käsmann; Alexander Dietrich; Claudia A Staab-Weijnitz; Farkhad Manapov; Jürgen Behr; Andreas Rimner; Branislav Jeremic; Suresh Senan; Dirk De Ruysscher; Kirsten Lauber; Claus Belka
Journal:  Radiat Oncol       Date:  2020-09-10       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.